News

Sarcoidosis Advocate Appointed Patient Advisor at aTyr

aTyr Pharma, which is developing a candidate therapy for pulmonary sarcoidosis called ATYR1923, has appointed Andrea Wilson — a sarcoidosis patient and advocate who co-founded the Foundation for Sarcoidosis Research (FSR) — as a patient advisor. “We are pleased during Sarcoidosis Awareness Month to welcome Andrea, a…

This April, Celebrate Sarcoidosis Awareness Month

From taking part in a virtual endurance challenge to joining in a virtual cooking class, to watching several speaker presentations, advocates are set to mark Sarcoidosis Awareness Month, observed each April. World Sarcoidosis Day will be celebrated on April 13. Awareness and education are crucial to increasing the recognition,…

Virtual Vigil Planned as Part of Sarcoidosis Awareness Month

April is Sarcoidosis Awareness Month and the Foundation for Sarcoidosis Research (FSR) is holding a virtual Memorial Monday Candlelight Vigil on April 26 to honor those who have died from the rare disease. The hour-long webinar starts at 5 p.m. CST and will feature a special tribute presentation and speakers. The…

Low Lymphocytes Levels Can Help Diagnose Active Sarcoidosis

An association has been found between active sarcoidosis, inflammation, and the presence of low levels of white blood cells, called lymphocytes, that are involved in immune defense. This finding, by researchers at the University of Illinois Chicago (UIC), could be the first step toward the development of a new biomarker…

Xentria Seeks to Begin Clinical Trial of XTMAB-16

Xentria is seeking regulatory approval to begin clinical trials to test XTMAB-16, its investigational TNF-alpha inhibitor for the treatment of sarcoidosis. Xentria submitted the request — in the form of an investigational new drug (IND) application — to the U.S. Food and Drug Administration (FDA) on Feb. 26. The…